ATE553122T1 - Antiangiogene methoden und zusammensetzungen - Google Patents
Antiangiogene methoden und zusammensetzungenInfo
- Publication number
- ATE553122T1 ATE553122T1 AT06736663T AT06736663T ATE553122T1 AT E553122 T1 ATE553122 T1 AT E553122T1 AT 06736663 T AT06736663 T AT 06736663T AT 06736663 T AT06736663 T AT 06736663T AT E553122 T1 ATE553122 T1 AT E553122T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- compositions
- antiangiogenic
- pedf
- retinopathies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65722405P | 2005-02-28 | 2005-02-28 | |
US67758405P | 2005-05-03 | 2005-05-03 | |
US71532605P | 2005-09-08 | 2005-09-08 | |
PCT/US2006/007382 WO2006094106A2 (en) | 2005-02-28 | 2006-02-28 | Anti-angiogenic methods and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE553122T1 true ATE553122T1 (de) | 2012-04-15 |
Family
ID=36829867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06736663T ATE553122T1 (de) | 2005-02-28 | 2006-02-28 | Antiangiogene methoden und zusammensetzungen |
Country Status (6)
Country | Link |
---|---|
US (5) | US7358085B2 (de) |
EP (2) | EP2314614B1 (de) |
JP (1) | JP4988606B2 (de) |
AT (1) | ATE553122T1 (de) |
CA (1) | CA2599004C (de) |
WO (1) | WO2006094106A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
CA2539288C (en) | 2003-09-15 | 2015-05-12 | Shaker A. Mousa | Thyroid hormone analogs and methods of use |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US8668926B1 (en) * | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
JP2009500297A (ja) * | 2005-06-08 | 2009-01-08 | セントカー・インコーポレーテツド | 眼の変性についての細胞療法 |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US9220788B2 (en) | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
WO2007035612A2 (en) | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
WO2007127408A2 (en) * | 2006-04-28 | 2007-11-08 | Tulane University Health Sciences Center | Methods for treating diabetes |
AU2007272313B2 (en) * | 2006-07-12 | 2013-11-21 | Mesoblast, Inc. | Treatment of excessive neovascularization |
US8319471B2 (en) | 2006-12-06 | 2012-11-27 | Solaredge, Ltd. | Battery power delivery module |
WO2008140507A2 (en) * | 2006-12-22 | 2008-11-20 | Clf Medical Technology Acceleration Program, Inc. | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
CN101883850B (zh) | 2007-07-12 | 2014-11-12 | 桑格摩生物科学股份有限公司 | 用于失活α-1,6岩藻糖基转移酶(FUT8)基因表达的方法和组合物 |
US8461303B2 (en) | 2007-08-02 | 2013-06-11 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
AU2009212247A1 (en) * | 2008-02-08 | 2009-08-13 | Sangamo Therapeutics, Inc. | Treatment of chronic pain with zinc finger proteins |
CA2741119C (en) | 2008-10-29 | 2019-02-12 | Sangamo Biosciences, Inc. | Methods and compositions for inactivating glutamine synthetase gene expression |
WO2010075332A1 (en) * | 2008-12-23 | 2010-07-01 | Charitable Leadership Foundation | Small molecule ligands of the integrin rgd recognition site and methods of use |
WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
WO2010091279A1 (en) * | 2009-02-06 | 2010-08-12 | Arresto Biosciences, Inc. | Methods and compositions for treatment of neovascularization |
EP2408921B1 (de) * | 2009-03-20 | 2017-04-19 | Sangamo BioSciences, Inc. | Modifikation von cxcr4 mit manipulierten zink-fingerproteinen |
WO2010120506A1 (en) * | 2009-03-31 | 2010-10-21 | Ordway Research Institute, Inc. | Combination treatment of cancer with cetuximab and tetrac |
RU2012110585A (ru) * | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Каталичические домены лизилоксидазы и loxl2 |
WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
US20110044981A1 (en) * | 2009-08-21 | 2011-02-24 | Spangler Rhyannon | Methods and compositions for treatment of pulmonary fibrotic disorders |
WO2011022709A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vitro screening assays |
MX2012002271A (es) * | 2009-08-21 | 2012-07-20 | Gilead Biologics Inc | Metodos y composiciones terapeuticas. |
US20120277144A1 (en) * | 2009-11-04 | 2012-11-01 | Henricus Johannes Duckers | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
CN105622757A (zh) | 2010-02-04 | 2016-06-01 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
AU2011316575B2 (en) | 2010-10-12 | 2015-10-29 | Sangamo Therapeutics, Inc. | Methods and compositions for treating hemophilia B |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
US20120239681A1 (en) | 2011-03-14 | 2012-09-20 | Splunk Inc. | Scalable interactive display of distributed data |
WO2013016434A1 (en) * | 2011-07-27 | 2013-01-31 | The Board Institute, Inc. | Compositions and methods of treating head and neck cancer |
US10570378B2 (en) | 2012-02-28 | 2020-02-25 | Sigma-Aldrich Co. Llc | Targeted histone acetylation |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
SI2890780T1 (sl) | 2012-08-29 | 2020-11-30 | Sangamo Therapeutics, Inc. | Postopki in sestavki za zdravljenje genetskega stanja |
US9941813B2 (en) | 2013-03-14 | 2018-04-10 | Solaredge Technologies Ltd. | High frequency multi-level inverter |
AU2015231353B2 (en) | 2014-03-18 | 2020-11-05 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
US9318974B2 (en) | 2014-03-26 | 2016-04-19 | Solaredge Technologies Ltd. | Multi-level inverter with flying capacitor topology |
CA3026504A1 (en) | 2016-06-07 | 2017-12-14 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with .alpha..nu..beta.3 integrin thyroid antagonists |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
CN114949208B (zh) * | 2022-05-06 | 2023-07-04 | 温州医科大学 | 纳米光动力材料及其脉络膜新生血管的治疗的应用 |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US653092A (en) * | 1899-12-11 | 1900-07-03 | Arthur F James | Necktie-fastener. |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5219739A (en) | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
EP0476983B1 (de) | 1990-09-21 | 2000-03-15 | Merck & Co. Inc. | Wachstumsfaktor II für vaskuläre Endothelzellen |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
EP0506477B1 (de) | 1991-03-28 | 1999-06-23 | Merck & Co. Inc. | Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6451763B1 (en) | 1992-06-04 | 2002-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Retinal pigmented epithelium derived neurotrophic factor and methods of use |
US6319687B1 (en) | 1992-09-24 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene |
US5840686A (en) | 1992-09-24 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use |
US5776755A (en) | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
US5503022A (en) | 1993-01-25 | 1996-04-02 | Barone; Larry A. | Marine impeller tester |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
EP0770129B1 (de) | 1994-01-18 | 2005-11-23 | The Scripps Research Institute | Derivate von zinkfingerproteinen und methoden |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DK0751992T3 (da) | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
AU698152B2 (en) | 1994-08-20 | 1998-10-22 | Gendaq Limited | Improvements in or relating to binding proteins for recognition of DNA |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6130071A (en) | 1997-02-05 | 2000-10-10 | Helsinki University Licensing, Ltd. | Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5607918A (en) | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
DE69630442T2 (de) | 1995-03-02 | 2004-08-19 | Amrad Operations Pty. Ltd., Richmond | Ein neuartiger wachstumsfaktor und eine genetische sequenz, die für diesen codiert |
US20020026037A1 (en) | 1995-06-06 | 2002-02-28 | Jing-Shan Hu | Vascular endothelial growth factor 3 antibodies |
AU710696C (en) | 1995-09-08 | 2002-10-24 | Genentech Inc. | VEGF-related protein |
AU1116297A (en) | 1995-11-08 | 1997-05-29 | Immunex Corporation | Flk-1 binding protein |
ATE306546T1 (de) | 1996-08-23 | 2005-10-15 | Ludwig Inst Cancer Res | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
US6131071A (en) * | 1996-12-06 | 2000-10-10 | Bp Amoco Corporation | Spectral decomposition for seismic interpretation |
WO1998024811A2 (en) | 1996-12-06 | 1998-06-11 | Zymogenetics, Inc. | Vascular endothelial growth factor |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
US5863736A (en) | 1997-05-23 | 1999-01-26 | Becton, Dickinson And Company | Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
CA2298018C (en) | 1997-07-23 | 2008-12-16 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
US6797691B1 (en) | 1997-07-23 | 2004-09-28 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
US6007408A (en) | 1997-08-21 | 1999-12-28 | Micron Technology, Inc. | Method and apparatus for endpointing mechanical and chemical-mechanical polishing of substrates |
EP1054687B8 (de) | 1997-12-24 | 2008-07-16 | Vegenics Limited | Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
JP4309051B2 (ja) | 1998-03-02 | 2009-08-05 | マサチューセッツ インスティテュート オブ テクノロジー | 改善したリンカーを有するポリジンクフィンガータンパク質 |
AU3072099A (en) | 1998-03-13 | 1999-09-27 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
WO2000045835A1 (en) | 1999-02-08 | 2000-08-10 | Human Genome Sciences, Inc. | Vascular endothelial growth factor-2 |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
CA2398155C (en) | 2000-01-24 | 2011-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for linking binding domains in nucleic acid binding proteins |
CA2407460C (en) | 2000-04-28 | 2013-06-25 | Sangamo Biosciences, Inc. | Targeted modification of chromatin structure |
DE60130645T2 (de) | 2000-04-28 | 2008-01-31 | Sangamo BioSciences, Inc., Richmond | Datenbanken von regulatorischen sequenzen, methoden zu ihrer herstellung und verwendung |
AU2001255748B2 (en) | 2000-04-28 | 2006-08-10 | Sangamo Therapeutics, Inc. | Methods for binding an exogenous molecule to cellular chromatin |
US6573092B1 (en) | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
US7026462B2 (en) | 2000-12-07 | 2006-04-11 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US20060193830A1 (en) * | 2002-03-20 | 2006-08-31 | Hauswirth William W | Raav vector compositions and methods for the treatment of choroidal neovascularization |
KR20060054196A (ko) * | 2003-06-10 | 2006-05-22 | 주식회사 툴젠 | 전달가능한 dna-결합 단백질 |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
-
2006
- 2006-02-28 AT AT06736663T patent/ATE553122T1/de active
- 2006-02-28 EP EP10185937.9A patent/EP2314614B1/de active Active
- 2006-02-28 WO PCT/US2006/007382 patent/WO2006094106A2/en active Application Filing
- 2006-02-28 EP EP06736663A patent/EP1869075B1/de not_active Not-in-force
- 2006-02-28 US US11/365,390 patent/US7358085B2/en active Active
- 2006-02-28 JP JP2007558205A patent/JP4988606B2/ja not_active Expired - Fee Related
- 2006-02-28 CA CA2599004A patent/CA2599004C/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/981,385 patent/US7795209B2/en active Active
- 2007-10-31 US US11/981,386 patent/US7893022B2/en active Active
- 2007-12-06 US US11/999,549 patent/US7732196B2/en active Active
-
2008
- 2008-01-09 US US12/008,245 patent/US8012946B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2599004A1 (en) | 2006-09-08 |
US20080118469A1 (en) | 2008-05-22 |
EP2314614B1 (de) | 2015-11-25 |
JP2008531056A (ja) | 2008-08-14 |
EP2314614A1 (de) | 2011-04-27 |
US20060210539A1 (en) | 2006-09-21 |
WO2006094106A2 (en) | 2006-09-08 |
US20080187523A1 (en) | 2008-08-07 |
US7358085B2 (en) | 2008-04-15 |
WO2006094106A3 (en) | 2007-02-15 |
EP1869075B1 (de) | 2012-04-11 |
US7893022B2 (en) | 2011-02-22 |
US7795209B2 (en) | 2010-09-14 |
US20080108556A1 (en) | 2008-05-08 |
CA2599004C (en) | 2015-05-26 |
US8012946B1 (en) | 2011-09-06 |
JP4988606B2 (ja) | 2012-08-01 |
EP1869075A2 (de) | 2007-12-26 |
US7732196B2 (en) | 2010-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE553122T1 (de) | Antiangiogene methoden und zusammensetzungen | |
MX2021006531A (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
MY158932A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
WO2016172658A3 (en) | Microbiome regulators and related uses thereof | |
CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
EA201001639A1 (ru) | Композиции и способы их получения и применения | |
UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
WO2008133663A3 (en) | Codon modified immunogenic compositions and methods of use | |
TW200720269A (en) | Apoptosis promoters | |
WO2009089635A9 (en) | Treating neurodegenerative diseases with progranulin (pgrn) | |
WO2007065010A3 (en) | Anti-angiogenesis compounds | |
WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
UA104626C2 (ru) | Анти-vegf антитело и его применение | |
WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
WO2007092622A3 (en) | Compositions and methods for treating bone | |
EP2450040A3 (de) | Zusammensetzungen und Kits zur Behandlung von Influenza | |
GB0710529D0 (en) | Vaccine | |
WO2009013543A3 (en) | Targeted binging agents directed to kdr and uses thereof - 035 | |
WO2010130830A3 (en) | Anti-sclerostin vhh and their use for treating bone diseases | |
WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
WO2014152965A3 (en) | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
MX2021008592A (es) | Composiciones de trem y usos de las mismas. |